FDA Approval Alert: The Need-to-Know | Subcutaneous Nivolumab in Solid Tumors

In December 2024, the FDA approved subcutaneous nivolumab and hyaluronidase-nvhy as a treatment for patients in all solid tumor indications for which nivolumab has already received approval.

Data from CheckMate-67T support the approval of subcutaneous nivolumab in patients with solid tumors where intravenous nivolumab was already approved.
FDA Approves Subcutaneous Nivolumab in All Solid Tumor Indications
Article
Dec 27, 2024 4:50 PM
Data from CheckMate-67T support the approval of subcutaneous nivolumab in patients with solid tumors across all previously approved nivolumab indications.